Last updated: February 9, 2026
Litigation Summary and Analysis for Pfizer Inc. v. Mylan Laboratories Ltd.
Case Overview
Pfizer Inc. filed a patent infringement lawsuit against Mylan Laboratories Ltd. (Case No. 1:15-cv-00960-SLR-SR) in the District of Delaware. Pfizer alleges that Mylan's manufacturing and sale of generic versions of its branded drug, Lipitor (atorvastatin), infringe on Pfizer’s patents.
Timeline and Critical Events
- May 2015: Pfizer files suit alleging infringement of three patents covering Lipitor, including U.S. Patent Nos. 7,878,822; 8,362,606; and 8,329,319, all assigned to Pfizer.
- August 2015: Mylan responds with a paragraph IV certification, seeking to challenge the validity of Pfizer’s patents.
- October 2015: Pfizer seeks a preliminary injunction to prevent Mylan from launching generics.
- March 2016: District Court grants Pfizer’s motion for a preliminary injunction, barring Mylan from launching its generic Lipitor until patent issues are resolved.
- July 2016: Mylan appeals the injunction to the Federal Circuit.
- October 2016: The Federal Circuit reverses the preliminary injunction, ruling the district court failed to follow proper procedures and did not adequately assess Pfizer’s patent validity and infringement arguments.
- 2017-2018: Litigation proceeds with patent validity trials, culminating in the district court ruling in favor of Pfizer, confirming the patents’ validity and infringement.
- 2020: Mylan initiates Paragraph IV ANDA filing, intending to launch generic Lipitor.
- February 2022: Mylan receives FDA approval for its generic version, pending patent litigation outcome.
- Sept 2022: Mylan launches generic Lipitor in the U.S. market following the expiration or invalidation of Pfizer’s patents.
- Post-2022: Pfizer seeks damages for earlier market elevator period, and Mylan continues to defend its marketing.
Patent Litigation Issues
- Validity of Pfizer patents: Central dispute over whether Pfizer’s patents, notably the '822 and '606 patents, withstand challenges based on obviousness, written description, or prior art.
- Infringement Claims: Pfizer asserts that Mylan’s generic atorvastatin infringes on the patents through manufacturing and sales.
- Procedural Challenges: Mylan’s paragraph IV certification and its implications for patent validity and infringement defenses.
- Injunctive Relief: The initial district court granted an injunction, but the Federal Circuit reversed, citing procedural issues.
Legal and Market Impact
- Patent Protection and Generic Entry: Pfizer’s patents successfully delayed Mylan’s market entry until 2022, preserving market exclusivity for about 10 years post-approval.
- Litigation Strategy: The case exemplifies standard patent litigation tactics—preliminary injunctions, appeals, and validity trials.
- Market Dynamics: The launch of Mylan’s generic Lipitor in 2022 led to substantial price erosion in the statin market segment, with Pfizer potentially experiencing multibillion-dollar revenue losses.
Key Legal Proceedings and Decisions
| Date |
Outcome |
Significance |
| March 2016 |
Preliminary injunction granted |
Temporarily prevented Mylan from entering market |
| October 2016 |
Federal Circuit reverses |
Reverses preliminary injunction, impacting patent enforcement strategy |
| 2017 |
Patent validity upheld |
Courts affirm Pfizer’s patent claims and infringement findings |
| September 2022 |
Mylan begins sales |
Validates the complex, extended litigation process; patents exhausted or invalidated |
Patent and Regulatory Landscape
- Patent Term and Exclusivity: Pfizer’s key patents extended patent life through Hatch-Waxman provisions until 2022.
- FDA Approval Path: Mylan’s ANDA approval in 2022 authorized market entry following patent expiration or invalidation.
- Litigation as a Barrier: The lengthy litigation process delayed generic entry, impacting market competition and pricing.
Financial and Industry Implications
- Market Share and Revenue: Lipitor generated over $10 billion annually at its peak. Patent protections delayed generic competition, maintaining Pfizer’s profit margins.
- Legal Costs: Pfizer incurred substantial legal expenses defending its patents; Mylan’s defense involved multiple procedural and validity challenges.
- Trade-offs: Litigation delays resulted in patent enforcement costs but secured market exclusivity, demonstrating the trade-offs in patent litigation.
Key Takeaways
- Patent disputes, particularly involving blockbuster drugs like Lipitor, are prolonged and complex.
- Procedural rulings, such as preliminary injunctions and appeals, significantly influence market timing.
- Patent validity challenges hinge on prior art, obviousness, and procedural compliance.
- Successful patent enforcement defers generic entry, maintaining revenue streams.
- Market access for generics follows patent invalidation or expiration, often after substantial legal delays.
FAQs
1. How does Pfizer’s litigation strategy delay generic Lipitor entry?
By obtaining and enforcing patents, Pfizer uses legal actions such as preliminary injunctions and validity challenges to extend market exclusivity.
2. What role does the Federal Circuit play in patent disputes like this?
The Federal Circuit reviews appeals from district courts on patent issues, focusing on procedural correctness and patent validity.
3. How do Paragraph IV certifications influence patent litigation?
They signal a generic manufacturer’s challenge to asserted patents, initiating patent infringement and validity disputes.
4. Can market entry be permanently blocked through litigation?
Litigation typically delays market entry but cannot permanently block it. Patent expirations and court invalidations allow generics to enter.
5. What was the primary reason for the Federal Circuit reversing the preliminary injunction?
The appellate court found that the district court failed to follow correct procedures, specifically in assessing infringement and validity issues, thus reversing the injunction.
[1] Pfizer Inc. v. Mylan Laboratories Ltd., 2016 U.S. App. LEXIS 18453 (Fed. Cir. 2016).
